Source briefingJuly 3, 2026Evidence
Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, imlifidase, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Renal and urinary disorders, PIP number: EMEA-002183-PIP03-23
Source digest: Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, imlifidase, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Renal and urinary disorders, PIP number: EMEA-002183-PIP03-23
FreedomWitness note: This is an automatically published source digest, not a copied full article. FreedomWitness links to the original source so readers can verify the full context.
Continue reading
Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial
by Yan Ning Li, Kumar S. D. Kothapalli, Susan E. Carlson, Byron J. Gajewski, Emily A. DeFranco, J. Thomas Brenna Background Spontaneous early preterm…
Heart attack, stroke — and hip fractures
Endocrinologist discusses life-or-death stakes of weak bones and how to protect against devastating falls
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products